KEY TAKEAWAYS
- The study aimed to assess OEP and CAPE effects on AML treatment and their synergy with MP.
- The study concluded that propolis and its constituents hold promise as valuable adjunctive therapies in chemotherapy.
Methylprednisolone (MP) is utilized in treating acute myeloid leukemia (AML), a systemic malignancy originating from hematological system abnormalities. Extensive cancer research focuses on propolis, a natural substance with considerable potential as adjunctive therapy. The application of propolis targets alleviating adverse effects of chemotherapy in AML treatment.
Hamide Dogan and the team aimed to assess the effects of OEP and CAPE on AML treatment and to investigate potential synergies with MP.
The proliferation of HL-60 cells was assessed using the WST-8 kit. DNA cell cycle analysis in OEP, CAPE, and MP-treated cells was performed via the PI Staining technique followed by flow cytometry.
Apoptotic status was determined by flow cytometry after Annexin V-APC kit staining. Apoptotic gene expression levels were quantified in HL-60 cells. The IC50 values of CAPE and MP in HL-60 cells were found to be 1 × 10-6 M and 5 × 10-4 M, respectively. Treatment with MP, CAPE, and OEP induced apoptosis and arrested HL-60 cells in the cell cycle’s G0/G1 and G2/M phases.
The study found that propolis and its constituents exhibit promise as valuable adjunctive therapies in chemotherapy.
Source: https://pubmed.ncbi.nlm.nih.gov/38643306/
Dogan H, Ozcimen AA, Silici S. (2024) “Interaction of olive oil-based propolis and caffeic acid phenethyl ester with methylprednisolone used in the treatment of human acute myeloid leukemia.” Mol Biol Rep. 2024 Apr 20;51(1):559. doi: 10.1007/s11033-024-09493-7. PMID: 38643306.
